Acute Ischemic StrokePhase 3TREND-IVTNCT06548971
Early Antiplatelet Administration After Intravenous Thrombolysis for Acute Ischemic Stroke (TREND-IVT)
A Phase 3 study testing Aspirin and Best medical management in people with Acute Ischemic Stroke and Cerebral Infarction, run by Capital Medical University at 119 sites in China.
Trial summary
Stroke is the second leading cause of death worldwide, and ischemic stroke is the most frequent type. Intravenous thrombolysis with recombinant tissue plasminogen activator within 4.5 hours of symptom onset is the most effective therapy for patients with acute ischemic stroke. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Acute Ischemic Stroke, Cerebral Infarction
- What is being tested?
- Aspirin and Best medical management
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 1,184 participants
- Where
- 119 sitesChina
- Study dates
- 7 Nov 2024to Dec 2027
- Phase
- Phase 3
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥18 years old;
- Acute ischemic stroke treated with intravenous thrombolysis with alteplase or tenecteplase within 4.5 hours of onset or time last known well, and can receive the study drug treatment within 3 hours of initiating intravenous thrombolysis.
- Residual NIHSS score > 5 points assessed 1 hour after initiation of intravenous thrombolysis and prior to randomization.
- Informed consent obtained from patients or an authorized representative.
Who cannot join
- Stroke caused by definite large vessel occlusion (including A1/A2 segments of the anterior cerebral artery, M1/M2 segments of the middle cerebral artery, P1/P2 segments of the posterior cerebral artery, intracranial/extracranial segments of the internal carotid artery, basilar artery, and bilateral vertebral artery occlusion) confirmed by vessel imaging (including computed tomography angiography [CTA] or magnetic resonance angiography [MRA]), or scheduled for endovascular treatment (including mechanical thrombectomy, intra-arterial thrombolysis, and angioplasty).
- Intracranial hemorrhage confirmed by imaging post-thrombolysis.
- Definite or suspected cardioembolic stroke.
- Stroke caused by other determined causes, including nonatherosclerotic vasculopathies (moyamoya disease, artery dissection, arteritis), hypercoagulable states, or hematological disorders.
- Use of antiplatelet therapy within one week prior to stroke onset, novel anticoagulant drugs within 48 hours prior to stroke onset, or treatment with warfarin with an international normalized ratio (INR)>1.7.
- Prior history of moderate or severe ischemic stroke events with residual neurological disability.
Show all 18Show fewer
- Pre-stroke mRS score > 1.
- Severe consciousness disturbance with NIHSS item 1a (level of consciousness) ≥ 2 points.
- Post-thrombolysis imaging indicates an infarct area larger than 1/2 responsible artery supply area.
- Known contraindications for antiplatelet therapy, such as coagulation disorders, or systemic bleeding
- History of aspirin allergy.
- Anticipated indications for anticoagulant therapy during the study period (e.g., atrial fibrillation, mechanical heart valve, deep vein thrombosis, pulmonary embolism, antiphospholipid syndrome, hypercoagulable state)
- Presence of malignant tumors, chronic hemodialysis, severe renal insufficiency (GFR < 30 mL/min or serum creatinine > 220 μmol/L [2.5 mg/dL]), severe hepatic insufficiency (serum alanine aminotransferase [ALT] >2 times the upper limit of normal, or serum aspartate aminotransferase [AST] >2 times the upper limit of normal), severe heart failure (New York Heart Association [NYHA] Functional Classification Class III or IV)
- Severe non-cardiovascular complications with an expected survival of less than 6 months.
- Unavailability for follow-up.
- Presence of dementia, psychiatric disorders, or other known neurological conditions that complicate follow-up.
- Current participation in another therapeutic study with ongoing treatment and follow-up.
- Other conditions that make the patient unsuitable for participation in the study as determined by the investigator.
Trial locations and contacts
119 sites in 1 country. Contact the study team or a site near you to ask about taking part.
119 sites in 1 country
China119 sites, 119 recruiting
- Not yet recruiting
Anshan Changda hospital
Anshan, Liaoning, 114000
Fan Zhang, M.D.
- Recruiting
Hua county People's Hospital
Anyang, Henan, 456400
Hongling Guo
- Not yet recruiting
Baoji Fengxiang district hospital
Baoji, Shanxi, 721400
Wei Song
- Recruiting
Xuanwu Hospital, Capital Medical University
Beijing, Beijing Municipality, 100053
Wenbo Zhao, M.D., +86-10-8319-9439, zhaowb@xwh.ccmu.edu.cn
- Recruiting
The Third The People's Hospital Of Bengbu
Bengbu, Anhui, 233000
Bin Ye, M.D.
- Recruiting
Huaiyuan county traditional Chinese medicine hospital
Bengbu, Anhui, 233400
Dlin Wang
- Not yet recruiting
Bozhou people's hospital
Bozhou, Anhui, 236800
Xiaofang Wu
- Recruiting
Cangzhou combination of Chinese traditional and western medicine hospital
Cangzhou, Hebei, 061001
Yonglin Shan
- Recruiting
Cangzhou Central Hospital
Cangzhou, Hebei, 061012
Zhen Hong, M.D.
- Recruiting
Botou traditional Chinese medicine hospital
Cangzhou, Hebei, 062150
Hemei Zhang
- Recruiting
Xian county People's Hospital
Cangzhou, Hebei, 062200
Xiangtao Wu
- Recruiting
Hejian city People's Hospital
Cangzhou, Hebei, 062450
Lixin Wu
- Recruiting
The First People's Hospital of Changde City
Changde, Hunan, 415000
Jun Wen
- Not yet recruiting
Li county people's hospital
Changde, Hunan, 415500
Jing Zhang
- Not yet recruiting
Xiangya Hospital Centralsouth University
Changsha, Hunan, 410013
Shuntong Hu
- Recruiting
Chengdu Second People's Hospital
Chengdu, Sichuan, 610041
Changchuan Wu
- Recruiting
Chenzhou first people's hospital
Chenzhou, Hunan, 424499
Ganghua Feng, M.D.
- Recruiting
Lvshunkou district traditional Chinese medicine hospital
Dalian, Liaoning, 116045
Changhao Jiang
- Recruiting
Donggang city Central Hospital
Dandong, Liaoning, 118300
Jing Li
- Recruiting
Datong third people's hospital
Datong, Shanxi, 037000
Dang Wang
- Recruiting
Ningjin county people's hospital
Dezhou, Shandong, 253400
Jian Zhang
- Recruiting
Dongying people's hospital
Dongying, Shandong, 257029
Wenjun Zhang
- Recruiting
Shengli oilfield central hospital
Dongying, Shandong, 257034
Ye Lang
- Recruiting
Fushun Mining Bureau General Hospital
Fushun, Liaoning
Hong 113012 Zhang, M.D.
- Recruiting
Fuxin people's hospital
Fuxin, Liaoning, 123000
Xiaolu Sun
- Recruiting
Fujian university affiliated provincial hospital
Fuzhou, Fujian, 350001
Yingchao He
- Recruiting
Brain Hospital Affiliated to Guangzhou Medical University
Guangzhou, Guangdong, 510180
Lixuan Zhan, M.D.
- Recruiting
Liuyang Jili Hospital
Guankou, Hunan, 410300
Yong He, M.D.
- Recruiting
Guigang people's hospitalv
Guigang, Guangxi, 537100
Xinming Li
- Recruiting
Harbin 242 hospital
Haerbin, Heilongjiang, 150066
Wei Zhang
- Recruiting
Aerospace central hospital
Haidian, Beijing Municipality, 100049
Peifu Wang
- Recruiting
The Second Affiliated Hospital of Hainan Medical University
Haikou, Hainan, 570145
Bin Liu
- Recruiting
The Third People's Hospital of Hubei Province
Hainan, Hubei, 430033
Fangyan Gong
- Recruiting
Handan Central Hospital
Handan, Hebei, 056001
Shejun Feng
- Recruiting
Handan first hospital
Handan, Hebei, 056002
Liping Cheng
- Recruiting
Ci county people's hospital
Handan, Hebei, 056500
Yanwei Xu
- Recruiting
Handan Yongnian District First Hospital
Handan, Hebei, 057150
Teng Ma
- Recruiting
Jun county people's hospital
Hebi, Henan, 458030
Beihai Jiang
- Recruiting
Heyuan people's hospital
Heyuan, Gangdong, 517000
Ying Xie
- Not yet recruiting
People's Hospital of Longchuan County
Heyuan, Guangdong, 517300
Linping Wei
- Recruiting
Huaibei people's hospital
Huaibei, Anhui, 235000
Chao Wang
- Recruiting
Jiamusi university hongda hospital
Jiamusi, Heilongjiang, 154002
Changsi Ai
- Recruiting
Jiaozuo Second People's Hospital
Jiangzuo, Henan, 454001
Bo LI
- Recruiting
Haiyan People's Hospital
Jiaxing, Zhejiang, 314311
Zhenhua Xi, M.D.
- Recruiting
Shandong province qianfoshan hospital
Jinan, Shandong, 250014
Weili Li
- Recruiting
Jinan Third People's Hospital
Jinan, Shandong, 250101
Peng Guo, M.D.
- Recruiting
Jingdezhen NO.1 People's Hospital
Jingdezhen, Jiangxi, 333000
Mingchao Wu, M.D.
- Not yet recruiting
Jingmen people's hospital
Jingmen, Hubei, 448000
Wei Li
- Recruiting
Jiaxiang county people's hospital
Jining, Shandong, 272400
Yapeng Sun
- Recruiting
Kaifeng central hospital
Kaifeng, Henan, 475000
Xinsheng Han
- Recruiting
The Second Affiliated Hospital of Guizhou Medical University
Kaili, Guizhou, 556099
Changsong Wu, M.D.
- Recruiting
Donghai county people's hospital
Lianyungang, Jiangsu, 222300
Yong Wang
- Recruiting
Liaocheng people's hospital
Liaocheng, Shandong, 252000
Weidong Liu
- Recruiting
The Third People Hospital In Liaocheng
Liaocheng, Shandong, 252000
Ke Diao, M.D.
- Recruiting
Gaotang county people's hospital
Liaocheng, Shandong, 252800
Huqing Li, M.D.
- Not yet recruiting
Linfen people's hospital
Linfen, Shanxi, 041000
Junfang Hao
- Recruiting
Lengshuijiang People's Hospital
Loudi, Hunan, 417500
Yan Zhang
- Recruiting
First People's Hospital of Luoyang
Luoyang, Henan, 471000
Jinfeng Shi
- Recruiting
Luoyang yiluo hospital
Luoyang, Henan, 471000
Yajun Yang
- Recruiting
Mengjin county people's hospital
Luoyang, Henan, 471100
Haojin Zhao
- Recruiting
Luoyang Yanshi People's Hospital
Luoyang, Henan, 471900
Yang Zhou, M.D.
- Recruiting
Mudanjiang first people's hospital
Mudanjiang, Heilongjiang, 157000
Pengfei Yu
- Recruiting
The Second Affiliated Hospital Of Nanchang University
Nanchang, Jiangxi, 330008
Jianglong Tu, M.D.
- Recruiting
Nanyang Central Hospital
Nanyang, Henan, 473000
Jun Sun
- Recruiting
Nanyang nanshi hospital
Nanyang, Henan, 473010
Junfeng Shi, M.D.
- Recruiting
Togtoh county hospital
Neimeng, Neimeng, 010200
Meixiu Hao
- Recruiting
Beijing Pinggu District Hospital
Pinggu, Beijing Municipality, 101200
Yifei Cheng
- Recruiting
Nanle county people's hospital
Puyang, Henan, 457400
Tingting Zhang
- Recruiting
Pingdu city traditional Chinese medicine hospital
Qingdao, Shandong, 266700
Hong Sui
- Recruiting
The First Hospital Of Qiqihar
Qiqihar, Heilongjiang, 161005
Chenghe Sun, M.D.
- Recruiting
Juxian county people's hospital
Rizhao, Shandong, 276500
Jiawen Sun
- Recruiting
Rizhao traditional Chinese medicine hospital
Rizhao, Shandong, 276800
Lei Mu
- Recruiting
Huanghe Sanmenxia hospital
Sanmenxia, Henan, 472000
Meng Xue, M.D.
- Recruiting
Shangqiu Third People's Hospital
Shangqiu, Henan, 476000
Yaping Jing
- Recruiting
Sui county traditional Chinese medicine hospital
Shangqiu, Henan, 476000
Ying Li
- Recruiting
Shangqiu First People's Hospital
Shangqiu, Henan, 476100
Hong Yang
- Recruiting
Sui county people's hospital
Shangqiu, Henan, 476900
Yunchao Chao
- Recruiting
Ningling county people's hospital
Shangqucun, Henan, 476700
Zhixiang Sui
- Not yet recruiting
Shaodong county people's hospital
Shanyang, Hunan, 422800
Qiong Zhao
- Recruiting
Shenzhen Second People's Hospital
Shenzhen, Shenzhen, 518035
Pengcheng Fu
- Recruiting
Shihezi City People's Hospital
Shihezi, Xinjiang, 832000
Feng Chen, M.D.
- Recruiting
Suzhou municipal hospital
Suzhou, Anhui, 234000
Lei Zhang
- Recruiting
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215004
Qi Fang
- Recruiting
The Fourth Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215021
Qi Fang
- Recruiting
Shandong health group feicheng hospital
Taian, Shandong, 271614
Youfeng Si
- Recruiting
Yutian county Hospital
Tangshan, Hebei, 064100
Haijun Li
- Recruiting
Tianjin Xiqing hospital
Tianjin, Tianjin Municipality, 300380
Yuqing Han
- Recruiting
Affiliated Hospital of Inner Mongolia University for the Nationalities
Tongliao, Inner Mongolia, 028007
Yaoming Xu, M.D.
- Recruiting
Kezuo Zhongqi People's Hospital
Tongliao, Neimenggu, 029315
Yingjie Bai
- Recruiting
Beijing Luhe Hospital affiliated to Capital Medical University
Tongzhou, Beijing Municipality, 101149
Lipeng Cai
- Recruiting
Ulanqab Central Hospital
Ulanqab, Inner Mongolia, 012000
Shuzhen Gong, M.D.
- Recruiting
Weifang people's hospital
Weifang, Shandong, 261041
Weili Li
- Recruiting
Weihai Municipal Hospital
Weihai, Shandong, 264200
Weibin Zhong, M.D.
- Recruiting
Weihai Central Hospital
Weihai, Shandong, 264400
Honghao Man
- Recruiting
Wenshan Zhou people's hospital
Wenshan, Yunnan, 663099
Jinghan Hu
- Recruiting
Wuzhou Red Cross Hospital
Wuzhou, Guangxi, 543002
Xuan Chen, M.D.
- Recruiting
The First Affiliated Hospital Of Xiamen University
Xiamen, Fujian, 361003
Yihong Zhan, M.D.
- Recruiting
Xiamen Xinglin hospital
Xiamen, Fujian, 361020
Caitang Wu, M.D.
- Recruiting
Xiangtan Central Hospital
Xiangtan, Hunan, 411100
Yong Liang, M.D.
- Not yet recruiting
Xiangxiang people's hospital
Xiangxiang, Hunan, 411400
Weijun Zhou
- Recruiting
Xiangyang central hospital
Xiangyang, Hubei, 441000
Jing Yang
- Not yet recruiting
Tuquan county people's hospital
Xingan, Neimeng, 137500
Ying Han
- Recruiting
Qinghe county people's hospital
Xingtai, Hebei, 054800
Yingzhuo Zang
- Recruiting
Xingtai ninth hospital
Xingtai, Hebei, 055250
Jinbo Yang
- Not yet recruiting
Xixian county people's hospital
Xinyang, Henan, 464300
Ruiyi Wang
- Recruiting
Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, 221006
Yu Feng
- Recruiting
Xuzhou Xin health hospital
Xuzhou, Jiangsu, 221007
Yu Chen
- Not yet recruiting
Jiawang district People's Hospital
Xuzhou, Jiangsu, 221120
Chengdong Ge
- Recruiting
Fengxian county people's hospital
Xuzhou, Jiangsu, 221700
Jiamin Liu
- Recruiting
Ya 'an People's Hospital
Ya'an, Sichuan, 625000
Jian Wang
- Recruiting
Ningyuan county People's Hospital
Yongzhou, Hunan, 425600
Zhenjun Yang
- Recruiting
Zha Lan Tun Shi Zhong Meng Yi Yuan
Zhalantun, Inner Mongolia, 162650
Chengyan Yang, M.D.
- Recruiting
Zhangzhou Hospital of Fujian Province
Zhangzhou, Fujian, 363000
Tingyu Yi
- Recruiting
Xihua People's Hospital
Zhoukou, Henan, 466000
Chaoqun Li, M.D.
- Recruiting
Shenqiu county People's Hospital
Zhoukou, Henan, 466399
Yanling Li
- Recruiting
Luyi county people's hospital
Zhoukou, Henan, 477200
Hao Liang
- Recruiting
Zhumadian Central Hospital
Zhumadian, Henan, 463000
Ligong Gao
- Recruiting
Zhuzhou Central Hospital
Zhuzhou, Hunan, 412007
Zhen Zhao, M.D.
- Recruiting
Zibo Central Hospital
Zibo, Shandong, 255020
Chao Wang, M.D.
About this study
Official title: Safety and Efficacy of Treatment With Early Antiplatelet Administration After Intravenous Thrombolysis for Acute Ischemic Stroke (TREND-IVT): A Multicenter, Randomized, Placebo-controlled, Clinical Trial
Stroke is the second leading cause of death worldwide, and ischemic stroke is the most frequent type. Intravenous thrombolysis with recombinant tissue plasminogen activator within 4.5 hours of symptom onset is the most effective therapy for patients with acute ischemic stroke. However, ischemic stroke progression and early reocclusion are not an uncommon phenomenon in patients after intravenous thrombolysis, resulting in neurological deterioration, which is associated with unfavorable functional outcomes. The underlying mechanism mainly involves the augmented platelet activation, triggered by the activated coagulation cascade during thrombolysis, which peaks within 2 hours of initiating rt-PA administration. Therefore, early antiplatelet therapy following intravenous thrombolysis represents a promising therapeutic approach to prevent neurological deterioration and improve the functional outcome of patients treated with intravenous thrombolysis.
Currently, guidelines recommend initiating antiplatelet therapy 24 hours after intravenous thrombolysis due to the potential risk of increased bleeding. The safety and efficacy of early antiplatelet treatment following intravenous thrombolysis in patients with acute ischemic stroke remain clear.
The study aims to test the hypothesis that in patients with acute ischemic stroke treated with intravenous thrombolysis, early administration of oral aspirin will improve functional outcomes without increasing the risk of intracranial hemorrhage.
- Conditions
- Acute Ischemic Stroke, Cerebral Infarction
- Being tested
- Aspirin, Placebo, Best medical management
- Keywords
- Acute ischemic stroke, Intravenous thrombolysis, Early neurological deterioration, Aspirin
- Medical subject headings
- Ischemic Stroke, Cerebral Infarction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AspirinDrug
Patients in the interventional group will chew 300mg of aspirin enteric-coated tablets as soon as possible after randomization. If swallowing difficulties arise, the tablets can be crushed and administered via a nasogastric tube.
PlaceboDrug
Patients in the control group will chew 300mg of placebos as soon as possible after randomization. If swallowing difficulties arise, the placebo can be crushed and administered via a nasogastric tube.
Best medical managementOther
Patients in both groups will receive the best medical management according to the guidelines.
| Study group | Role | What they receive |
|---|---|---|
| Interventional group | Experimental | Patients in the interventional group will receive early antiplatelet treatment with oral aspirin within 3 hours of initiating intravenous thrombolysis. In addition, the best medical management will be administered according to the guidelines. Receives: Drug: Aspirin; Other: Best medical management |
| Control group | Placebo comparator | Patients in the control group will receive placebos within 3 hours of initiating intravenous thrombolysis. In addition, the best medical management will be administered according to the guidelines. Receives: Drug: Placebo; Other: Best medical management |
What is being measured
The primary outcome is the main question the study is designed to answer.
The proportion of patients with a modified Rankin scale (mRS) score of 0-1 at 90-day follow up.
The mRS ranges from 0 to 6, with higher scores indicating a worse outcome. The primary outcome measure is based on the mRS score, which is dichotomized to define the excellent functional outcome as mRS score of 0-1 at 90-days follow up.
Measured: Ninety days after stroke.
Secondary outcomes (6)
The proportion of patients with a modified Rankin scale (mRS) score of 0-1 at 30-day follow up.
The mRS ranges from 0 to 6, with higher scores indicating a worse outcome. The primary outcome measure is based on the mRS score, which is dichotomized to define the excellent functional outcome as mRS score of 0-1 at 30-days follow up.
Measured: Thirty days after stroke.
The proportion of patients with a modified Rankin scale (mRS) score of 0-2 at 90-day follow up.
The mRS ranges from 0 to 6, with higher scores indicating a worse outcome. Functional independence is defined as mRS of 0-2.
Measured: Ninety days after stroke.
The shift analysis in the 90-day modified Rankin scale (mRS) score.
The mRS ranges from 0 to 6, with higher scores indicating a worse outcome.
Measured: Ninety days after stroke.
The proportion of patients achieving neurological improvement.
Neurological improvement is defined as a decrease of ≥2 points in the NIHSS score at 48 hours of randomization compared to baseline assessment.
Measured: Within 48 hours after stroke.
The proportion of patients experiencing early neurological deterioration.
Early neurological deterioration is defined as an increase of ≥4 points in the NIHSS score within 24 hours of randomization compared with the minimum NIHSS score before deterioration.
Measured: Within 24 hours after stroke.
The changes in the NIHSS score at 24 hours, 48 hours, and 7 days of enrollment as compared with the baseline.
The NIHSS ranges from 0 to 42 points, with higher scores indicating worse neurological deficits.
Measured: Within 7 days after stroke.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Aug 2024
- Study start7 Nov 2024
- Primary completionDec 2027 (estimated)
- Study completionDec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (6)Papers the sponsor has linked to this study.
- Other trials for Acute Ischemic StrokeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 1,184 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Capital Medical University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ji Xunming,MD,PhD, Capital Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06548971
- Sponsor's protocol ID
- TREND-IVT
- Acronym
- TREND-IVT
- Status last verified
- Sep 2026
- First submitted
- 3 Aug 2024
- Last updated
- 24 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M, Demaerschalk BM, Hoh B, Jauch EC, Kidwell CS, Leslie-Mazwi TM, Ovbiagele B, Scott PA, Sheth KN, Southerland AM, Summers DV, Tirschwell DL. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2019 Dec;50(12):e344-e418. doi: 10.1161/STR.0000000000000211. Epub 2019 Oct 30.
PubMed 31662037Demaerschalk BM, Kleindorfer DO, Adeoye OM, Demchuk AM, Fugate JE, Grotta JC, Khalessi AA, Levy EI, Palesch YY, Prabhakaran S, Saposnik G, Saver JL, Smith EE; American Heart Association Stroke Council and Council on Epidemiology and Prevention. Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2016 Feb;47(2):581-641. doi: 10.1161/STR.0000000000000086. Epub 2015 Dec 22.
PubMed 26696642Wu C, Sun C, Wang L, Lian Y, Xie N, Huang S, Zhao W, Ren M, Wu D, Ding J, Song H, Wang Y, Ma Q, Ji X. Low-Dose Tirofiban Treatment Improves Neurological Deterioration Outcome After Intravenous Thrombolysis. Stroke. 2019 Dec;50(12):3481-3487. doi: 10.1161/STROKEAHA.119.026240. Epub 2019 Oct 1.
PubMed 31570084Zinkstok SM, Roos YB; ARTIS investigators. Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial. Lancet. 2012 Aug 25;380(9843):731-7. doi: 10.1016/S0140-6736(12)60949-0. Epub 2012 Jun 28.
PubMed 22748820Zhao W, Li S, Li C, Wu C, Wang J, Xing L, Wan Y, Qin J, Xu Y, Wang R, Wen C, Wang A, Liu L, Wang J, Song H, Feng W, Ma Q, Ji X; TREND Investigators. Effects of Tirofiban on Neurological Deterioration in Patients With Acute Ischemic Stroke: A Randomized Clinical Trial. JAMA Neurol. 2024 Jun 1;81(6):594-602. doi: 10.1001/jamaneurol.2024.0868.
PubMed 38648030Wang J, Li S, Liu L, Ma Q, Li C, Wu C, Wu L, Song H, Ji X, Zhao W. Safety and Efficacy of Early Aspirin Administration After Intravenous Thrombolysis for Acute Ischemic Stroke (TREND-IVT): Rationale and Design of a Multicenter, Randomized, Placebo-Controlled Clinical Trial. J Am Heart Assoc. 2026 Mar 3;15(5):e045180. doi: 10.1161/JAHA.125.045180. Epub 2026 Feb 20.
PubMed 41717940